All News

podcast logo

RheumNow Podcast – ACR 2020 Epilogue (11.20.20)

d Jack Cush, MD

Dr. Jack Cush reviews a few more ACR 2020 abstracts and presents a new plan to learn or take in ACR20 content.

Read Article
What is the SEAMless transition from combination Etanercept to Methotrexate? with Dr. Jonathan Kay #ACR20 https://t.co/58raeaE8Mr https://t.co/FUIidcoy4I

Links:

Dr. John Cush RheumNow ( View Tweet)
SEAM-RA Trial: Dr. Jeff Curtis ( @RADoctor) discusses abstract # 0939 that looked at whether RA patients at or close to remission should continue taking their combination therapy, as presented at #ACR20 https://t.co/2yMyj4BKs1 https://t.co/2gqJM4EKpG

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. David Liew ( @drdavidliew) reviews abstracts #0431 on HCQ and QTc Prolongation as presented at #ACR20. https://t.co/vbqf7UNzVY https://t.co/qBCqFqYQCo

Links:

Dr. John Cush RheumNow ( View Tweet)
covid19.logo_.jpg

COVID and Rheumatic Disease Patients: Dr. Kevin Winthrop

d Kevin Winthrop, MD, MPH

Portland-based Dr. Kevin Winthrop from OHSU discusses Saturday ACR 2020 posters #0623 and #0629 related to COVID-19 and rheumatic disease patients.

Read Article
Methotrexate Induced Liver Fibrosis: Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract #0205 presented Friday at the #ACR20 annual meeting. https://t.co/P80WIGXOPg https://t.co/xEAuxSqIQv

Links:

Dr. John Cush RheumNow ( View Tweet)
podcastLogo-01%20RESIZED.jpg

Rheumnow Podcast - ACR 2020 Retrospective (11.13.20)

d Jack Cush, MD

Dr. Jack Cush reviews this past week at Virtual ACR 2020 - highlights from the meeting and his view of best/newest studies.

What will people remember or talk about from ACR 2020?

Read Article
ACR20 Podcast

ACR20 - Day 5.1 & 5.2 Podcasts

d Jack Cush, MD

Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.



Listen here:

Read Article
ACR Mon

ACR20 - Day 4 Report

d Jack Cush, MD

Here are my highlights from day four, Monday, of the ACR 2020 Convergence. 



Vaccine Immunogenicity with Tofacitinib

Read Article
ACR20 Podcast

ACR20 - Day 5 Podcast

d Jack Cush, MD

Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.



Listen here:

Read Article
ACR20 Podcast

ACR20 - Day 4.6 & 4.7 Podcasts

d Jack Cush, MD

Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.



Listen here:

Read Article
ACR20 Podcast

ACR20 = Day 4.4 & 4.5 Podcasts

d Jack Cush, MD

Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.



Listen here:

Read Article
Roundup RHeum ACR

Rheumatology Round-Up with Drs. Kavanaugh & Cush

d Jack Cush, MD

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!


Read Article
Best of

ACR Best Abstracts - Day 4

d Jack Cush, MD

The final day (day 4) of the ACR 2020 meeting saw a flurry of late-breaking abstracts and other novel studies that excited our faculty. Below are some of their choices for #ACRbest.

Read Article
Inadequate response to MTX, what next? “Are you forward thinking or are you stuck in the past? Conceptually it is just amazing that you can take a PO tablet as potent as a TNF or IL6 blocker... & the side effects are not so appalling.”—Dr. GreggSilverman. @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

When do you think we are going to get a DMARD for OA? 50% or more over age 60 will have osteoarthritis, yet we are yet to discover a promising disease modifying therapy. #ACR20 @RheumNow @ElaineHusniMD

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Summary of #ACR20 part A: - HCQ is not a problem in rheumatic dz pts in terms of causing QTc prolongation - Anti-phospholipid ab are found in a majority of hospitalized COVID19 pts — the most prevalent of which were anti-PST abs that are not in the of criteria for APS @rheumnow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Abst#2001: Heme changes on MTX? CIRT trial (non-rheumatic pts): Low-dose MTX (15-20mg/w): 2 line cytopenia uncommon (4%), pancytopenia rare (0.5%), Hb decrease 0.4 g/dL but WBC, plt unchanged. Reassuring large pop study shows tolerance of MTX #ACR20 @Rheumnow

Eric Dein ejdein1 ( View Tweet)

Abst#2000. PRIME team Medicare database study pts with new RA started on MTX higher VTE risk than HCQ (HR 2.3). Unable to assess disease activity because claims database, but would imagine MTX grp more severe, driving increased VTE risk @RheumNow #ACR20 https://t.co/Z14xFTVXTp
Eric Dein ejdein1 ( View Tweet)
COX2 inhibitors associated with inhibition of radiographic spinal progression in AxSpA pts compared to non-selective NSAIDs. ⬇️radiographic spinal progression over 2 yrs ⬇️mSASSS progression @RheumNow #ACR20 Abs#2030 https://t.co/p1CeNBm3ma
Robert B Chao, MD doctorRBC ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.